Clinical trial · Observational
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
An Observational, Multi-centre Study on EGFR T790M Mutation Testing Practices and Outcomes Conducted Among Locally Advanced/Metastatic NSCLC Patients Who Progressed on Previous EGFR Tyrosine-kinase Inhibitor (TKI) Therapy in Hong Kong
NCT03519958CI-TRIAL-00035834withdrawnClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): The study direction does not longer aligns the sponsor's strategy
Summary
Brief summary (as posted)
To describe the T790M mutation status of patients with locally advanced/metastatic NSCLC who progressed on previous EGFR TKI treatment in a real-world setting.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Plasma-tissue testing | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- EGFR NSCLC Progressed on EGFR TKI
- description
- Patients with EGFR NSCLC who have progressed following EGFR TKI therapy will undergo plasma-tissue testing
- interventionNames
- Diagnostic Test: Plasma-tissue testing
Primary outcomes (1)
- measure
- EGFR T790M mutation prevalance
- timeFrame
- 3 years
- description
- Based on the plasma-tissue testing algorithm in NSCLC patients who progressed on previous EGFR TKI therapy
Secondary outcomes (10)
- measure
- Proportion of Valid Tissue T790M Testing Result
- timeFrame
- 3 years
- description
- Proportion of study subjects who have a valid tissue/cytology T790M testing result after receiving a negative plasma test result for the T790M mutation
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria * Provision of written informed consent * Locally advanced (stage IIIB) or metastatic (stage IV) NSCLC, not amenable to curative surgery or radiotherapy * Confirmed EGFR sensitizing mutation (exon 19 deletion or exon 21 L858R ) in medical record * Progressed on previous EGFR TKI treatment, based on physician judgement, with or without additional lines of treatment * Suggested to undergo T790M mutation testing by treating physician, based on physician judgement Exclusion Criteria * Had been treated with osimertinib or any other 3rd generation T790M inhibitors * Enrollment in studies that prohibit participation in this observational study
References
Publications (0)
Data not yet available
No reference posted for this study.